

IMP: Imperial Metagenomics Pipeline for high-throughput sequence data

Lesley Hoyles^{1,2}

James C. Abbott^{1,3}

Elaine Holmes¹

Jeremy K. Nicholson¹

Marc-Emmanuel Dumas¹

Sarah A. Butcher^{1,3}

¹Department of Surgery and Cancer, Faculty of Medicine, Imperial College London,

² Department of Biomedical Sciences, Faculty of Science & Technology, University of Westminster

³ Centre for Integrative Systems Biology and Bioinformatics, Division of Molecular Biosciences, Faculty of Natural Sciences, Imperial College London

This is a copy of the poster presented at the 'Exploring Human Host-Microbiome Interactions in Health and Disease' conference, held at Wellcome Trust Genome Campus, Cambridge, UK, June-July 2015.

Copyright © 2015 The Authors.

The WestminsterResearch online digital archive at the University of Westminster aims to make the research output of the University available to a wider audience. Copyright and Moral Rights remain with the authors and/or copyright owners.

Whilst further distribution of specific materials from within this archive is forbidden, you may freely distribute the URL of WestminsterResearch:
(<http://westminsterresearch.wmin.ac.uk/>).

In case of abuse or copyright appearing without permission e-mail
repository@westminster.ac.uk

Lesley Hoyles^{1,2} | James C. Abbott^{1,3} | Elaine Holmes¹ | Jeremy K. Nicholson¹ | Marc-Emmanuel Dumas¹ | Sarah A. Butcher^{1,3}

Taxonomic data could be used to split patients into disease and healthy groups (Figure 4).




Figure 4. Principal component analysis of genus-level data generated from MetaPhlAn 2.0 outputs. After removal of three outliers from the liver-cirrhosis group, patients could be separated based on health status. (L) Scores plot; (R) loadings plot.




Figure 2: Relative abundance of 15 bacterial genera in the fecal microbiota of healthy and liver disease mice. The chart shows that the relative abundance of several genera, including Bacteroides, Prevotella, Faecalibacterium, Eubacterium, Alistipes, Veillonella, Roseburia, Parabacteroides, Streptococcus, Escherichia, Ruminococcus, Blautia, Megamonas, Haemophilus, Clostridium, and Klebsiella, is significantly lower in liver disease mice compared to healthy mice (p < 0.05). The y-axis represents relative abundance from 0 to 80. The x-axis lists the bacterial genera. Blue bars represent healthy mice, and red bars represent liver disease mice. Error bars indicate standard deviation. Asterisks indicate statistical significance (p < 0.05).

Bacterial Genus	Healthy (Relative Abundance)	Liver Disease (Relative Abundance)
Bacteroides	~58	~48
Prevotella	~4	~20
Faecalibacterium	~12	~6
Eubacterium	~12	~10
Alistipes	~12	~5
Veillonella	~10	~10
Roseburia	~6	~5
Parabacteroides	~4	~3
Streptococcus	~5	~5
Escherichia	~4	~2
Ruminococcus	~4	~2
Blautia	~2	~2
Megamonas	~2	~2
Haemophilus	~2	~2
Clostridium	~2	~2
Klebsiella	~2	~2

Figure 3. MetaPhlAn 2.0 analyses of metagenomic data from [1] using IMP. In agreement with [1], *Bacteroidetes* and *Firmicutes* represented the most abundant taxa in patient samples; *Veillonella*, *Streptococcus*, *Clostridium* and *Prevotella* were enriched in the liver-cirrhosis group; and *Eubacterium* and *Alistipes* were amongst the most dominant bacteria in the healthy controls.

Selection of tools for use in the pipeline was made following assessment of numerous options; for example, a number of *de-novo* assemblers were assessed on both raw assembly statistics and a measure of potentially chimeric contigs produced, based upon the number of genera the reads associated with each contig originated from (Figure 6).

Figure 6. Results of comparison of *de-novo* metagenome assemblers

Although various tools have been selected for the different stages of the pipeline, the modular nature of the pipeline permits the ready replacement of these with alternatives should better or more appropriate methods become available in future.

Availability. Code is still being finalized, but will be available from www.ic.ac.uk/bioinfsupport/software when complete.

¹Qin *et al.* (2014). *Nature* **513**, 59–64.

²Li & Durbin (2009). *Bioinforma Oxf Engl* **25**, 1754–1760.

³Gouba & Drancourt (2015). *Med Mal Infect* **45**, 9–16.

⁴Segata *et al.* (2012). *Nat Methods* **9**, 811–814 .

⁵Peng et al. (2012). *Bioinforma Oxf Engl* **28**, 142

⁶Besemer & Borodovsky (1999). *Nucleic Acids Res* **27**, 39

⁷Zhu *et al.* (2010). *Nucleic Acids Res* **38**, e132.

⁸Edgar (2010). *Bioinformatics* **26**, 2460–2461.

⁹Jones *et al.* (2014). *Bioinformatics* **30**, 1236–1240.



FLORINASH contract N° Health-F2-2009-241913 is supported by funding under the Seventh Research Framework Programme of the European Commission

¹Division of Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, United Kingdom

²Department of Biomedical Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, United Kingdom

³Centre for Integrative Systems Biology and Bioinformatics, Division of Molecular Biosciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, United Kingdom

Contact Lesley Hoyles (lesley.hoyles11@imperial.ac.uk)